Intravenous infusion of autologous endothelial progenitor cells in treatment of primary pulmonary hypertension

Ma Caiyan,Chen Junzhu

DOI: https://doi.org/10.3969/j.issn.1006-2785.2006.07.003

2006-01-01

Abstract:Objective To investigate the feasibility, safety, and initial clinical outcome of intravenous infusion of autologous endothelial progenitor cell (EPC) in children with primary pulmonary artery hypertension. Methods EPC(0.5±0.3×107) were infused at the level of the pulmonary artery by right heart catherterization in 13 PPH children hospitalized. The primary end point for efficacy evaluation was change in the 6-minute walk distance using a standardized protocol. The secondary end points were changes in hemodynamic variables as assessed by right heart catheterization. Results The mean distance in 6-minute walk test increased from(230±56)m to(13± 65)m after 3 months (P<0.01). During the same period, the mean pulmonary arterial pressure declined from(62±10)mmHg to(53±12)mmHg(P<0. 01), cardiac output increased from(3.6±1.2)liters per minute to(4.2±1.1)liters per minute, and pulmonary vascular resistance declined from(1195±437)dyn. sec.cm-5 to(905± 427)dyn.sec.cm-5 (P<0. 01). There were no severe adverse events with cell infusion. Conclusion Intravenous infusion of autologous EPC appeared to be feasible and safe, and may have beneficial effects on exercise capacity and pulmonary hemodynamics in patients with idiopathic pulmonary arterial hypertension.